【摘要】 目的探讨血清鳞状细胞癌抗原(SCCAg)水平与鼻腔鼻窦鳞状细胞癌(NSCC)患者临床分期及治疗预后关系。方法采用微粒子酶免疫分析法(MEIA)检测河北省邢台市眼科医院29例NSCC患者治疗前后血清SCCAg水平。结果 29例NSCC患者血清SCCAg阳性率为86.2%(25/29),SCCAg阳性率与NSCC的TNM分期有关。治疗前后患者血清鳞状细胞癌抗原水平变化差异有统计学意义(P<0.05)。复发患者SCCAg明显升高。结论血清SCCAg可作为鼻腔鼻窦鳞癌的相关肿瘤标志物,对判断鼻腔鼻窦鳞癌治疗效果、预后有重要的临床意义。更多还原

【Abstract】 Objective To study the expression and relationship among clinical stage and therapy prognosis of squa mous cell carcinoma antigen(SCCAg) in NSCC patients.Methods The serum SCCAg levels were determined by microparticle enzyme-immunoassay(MEIA) in 29 patients with NSCC before and after the treatment.Results The SCCAg positive rates were 86.2% in 29 patients with NSCC,and the SCCAg positive rates had related with elevation of clinical stage.Serum of SCCAg in the patients with squamous cell carcinoma antigen level changed before and af ter treatment,the difference was statistically significant(P < 0.05).The SCCAg of relapsed patients significantly elevated.Conclusion SCCAg is an important tumor related marker for the patients with NSCC.It plays an important role in evaluating the therapeutic effects and prognosis in patients with NSCC.更多还原